CELC earnings analysis
What we found in CELC's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Celcuity remained pre-commercial in Q2 2026, reporting $0 revenue and adjusted EPS of -$1.07, which modestly beat the -$1.08 consensus estimate. The late Q3 2026 REVTORPYK launch outlook was maintained, and $557.2 million of net financing proceeds improved liquidity. However, operating cash use of $55.4 million and operating expenses of $66.1 million underscore substantial cash-burn and execution risks ahead of commercialization.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- EPS modestly beat consensus
- Revenue was $0, compared with the $400,000 consensus estimate, while adjusted EPS was -$1.07 versus the -$1.08 estimate, a modest $0.01 beat.
- Late Q3 2026 launch remains on track
- Management continued to expect REVTORPYK commercial launch and initial shipments in late Q3 2026; no quantitative revenue outlook was disclosed.
- $557.2M of financing proceeds
- The company reported $557.2 million of net financing proceeds, materially strengthening near-term liquidity for commercialization and development activities.
- VIKTORIA-1 showed stronger PFS
- VIKTORIA-1 clinical results showed stronger progression-free survival, supporting the company’s clinical and regulatory objectives.
- Controls remained effective
- Management concluded disclosure controls were effective as of June 30, 2026, and reported 0 material changes to internal control over financial reporting during the quarter.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- No commercial revenue
- Revenue was $0 versus the $400,000 estimate, highlighting the company’s continued pre-commercial status and dependence on the late Q3 2026 REVTORPYK launch.
- Elevated cash burn
- Operating cash use was $55.4 million, indicating elevated cash burn ahead of commercialization and increasing dependence on available financing.
- Higher operating expenses
- Operating expenses were $66.1 million, increasing the scale of losses before product revenue begins.
- No change to disclosed risks
- The filing reported 0 material changes to the risk factors previously disclosed in the 2025 10-K; therefore, no new risk-factor mitigation or reduction was identified.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-1.07
What they said about what is next.
No numeric revenue or EPS guidance was provided. Management maintained its outlook for REVTORPYK commercial launch and initial shipments in late Q3 2026.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 14, 2026
- Celcuity reported an actual net loss of $52.8 million for Q1 2026, translating to a diluted EPS of -$0.73, exceeding estimates by 29%. Operating expenses surged to $50.5 million, largely driven by increased R&D and SG&A…
- 10-K · March 26, 2026
- Celcuity is a clinical-stage oncology company whose lead candidate, gedatolisib, produced positive Phase 3 VIKTORIA-1 PIK3CA WT results and led to FDA acceptance of an NDA with Priority Review (PDUFA July 17, 2026). The…
- 10-Q · May 16, 2022
- Celcuity reported a wider Q1 net loss of $7,934,447 (Q1 2021: $2,791,668) and loss per share of $(0.53) (Q1 2021: $(0.25)), driven by a large increase in R&D spend to $6,696,313 (Q1 2021: $2,236,342). Cash declined to…
- 10-Q · November 9, 2021
- Celcuity reported no revenues and a wider quarterly loss: Q3 net loss was $(6,027,246) or $(0.41) per share versus $(2,474,298) or $(0.24) in the prior-year quarter. R&D spending accelerated to $4,960,515 (Q3 2021) as…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing CELC makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever